{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:12:59Z","timestamp":1793229179262,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32172800"],"award-info":[{"award-number":["32172800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFD1800405"],"award-info":[{"award-number":["2021YFD1800405"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.actbio.2024.09.026","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T01:21:31Z","timestamp":1726795291000},"page":"358-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Nanoparticles target M2 macrophages to silence kallikrein-related peptidase 12 for the treatment of tuberculosis and drug-resistant tuberculosis"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-0823","authenticated-orcid":false,"given":"Yuanzhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiduo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meizhen","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1566-5745","authenticated-orcid":false,"given":"Xiangmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0001","doi-asserted-by":"crossref","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0002","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO's Global Tuberculosis Report 2022","volume":"4","author":"Bagcchi","year":"2023","journal-title":"Lancet Microbe"},{"issue":"7","key":"10.1016\/j.actbio.2024.09.026_bib0003","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0004","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis\u2013advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.actbio.2024.09.026_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrd4696","article-title":"Towards host-directed therapies for tuberculosis","volume":"14","author":"Zumla","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1183\/09031936.00127807","article-title":"High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation","volume":"33","author":"Sheen","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.actbio.2024.09.026_bib0007","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1128\/IAI.02048-05","article-title":"Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection","volume":"74","author":"Taylor","year":"2006","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.actbio.2024.09.026_bib0008","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.4432","article-title":"Mycobacterium tuberculosis dysregulates MMP\/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation","volume":"235","author":"Kubler","year":"2015","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.actbio.2024.09.026_bib0009","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1165\/rcmb.2009-0034OC","article-title":"Absence or inhibition of matrix metalloproteinase-8 decreases ventilator-induced lung injury","volume":"43","author":"Albaiceta","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.actbio.2024.09.026_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197474","article-title":"Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas","volume":"13","author":"Ordonez","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0011","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/infdis\/jiy373","article-title":"Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology","volume":"219","author":"Ordonez","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"20","key":"10.1016\/j.actbio.2024.09.026_bib0012","doi-asserted-by":"crossref","first-page":"12257","DOI":"10.3390\/ijms232012257","article-title":"KLK12 Regulates MMP-1 and MMP-9 via Bradykinin Receptors: Biomarkers for Differentiating Latent and Active Bovine Tuberculosis","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt 4","key":"10.1016\/j.actbio.2024.09.026_bib0013","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1042\/BST0350686","article-title":"Astrocyte-leucocyte interactions and the mechanisms regulating matrix degradation in CNS tuberculosis","volume":"35","author":"Green","year":"2007","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1183\/09031936.00146510","article-title":"Series \"matrix metalloproteinases in lung health and disease\": Biological role of matrix metalloproteinases: a critical balance","volume":"38","author":"Loffek","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.actbio.2024.09.026_bib0015","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/35081571","article-title":"Metalloproteinases in biology and pathology of the nervous system","volume":"2","author":"Yong","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"issue":"15","key":"10.1016\/j.actbio.2024.09.026_bib0016","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1039\/D0TB02956D","article-title":"Targeting macrophages using nanoparticles: a potential therapeutic strategy for atherosclerosis","volume":"9","author":"Zang","year":"2021","journal-title":"J. Mater. Chem. B"},{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41569-021-00629-x","article-title":"Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis","volume":"19","author":"Chen","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.actbio.2024.09.026_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.747799","article-title":"Macrophage: A Cell With Many Faces and Functions in Tuberculosis","volume":"13","author":"Ahmad","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.actbio.2024.09.026_bib0019","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/smim.1998.0141","article-title":"The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity","volume":"10","author":"Fraser","year":"1998","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.actbio.2024.09.026_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2022.102394","article-title":"The mannose receptor ligands and the macrophage glycome","volume":"75","author":"Cummings","year":"2022","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"3","key":"10.1016\/j.actbio.2024.09.026_bib0021","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/ijms25031370","article-title":"Mannose Ligands for Mannose Receptor Targeting","volume":"25","author":"Paurevic","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0022","first-page":"17","article-title":"Nanoparticles\u2013a new colloidal drug delivery system","volume":"53","author":"Marty","year":"1978","journal-title":"Pharm. Acta Helv."},{"issue":"3","key":"10.1016\/j.actbio.2024.09.026_bib0023","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/ard.1995.5.213","article-title":"Bovine Serum-Albumin Is a Major Oligonucleotide-Binding Protein Found on the Surface of Cultured-Cells","volume":"5","author":"Geselowitz","year":"1995","journal-title":"Antisense Res. Dev."},{"issue":"1-2","key":"10.1016\/j.actbio.2024.09.026_bib0024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0378-5173(02)00300-9","article-title":"Albumin nanoparticles as carriers for a phosphodiester oligonucleotide","volume":"244","author":"Arnedo","year":"2002","journal-title":"Int. J. Pharmaceut."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2003.10.009","article-title":"Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide","volume":"94","author":"Arnedo","year":"2004","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.actbio.2024.09.026_bib0026","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/adma.201600213","article-title":"A Near-Infrared Laser-Activated \"Nanobomb\" for Breaking the Barriers to MicroRNA Delivery","volume":"28","author":"Wang","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2024.09.026_bib0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.addr.2016.06.011","article-title":"Recent progress in development of siRNA delivery vehicles for cancer therapy","volume":"104","author":"Kim","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.actbio.2024.09.026_bib0028","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tcb.2016.11.003","article-title":"Unique Intercellular Delivery Vehicles","volume":"27","author":"Maas","year":"2017","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.actbio.2024.09.026_bib0029","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2011\/742895","article-title":"Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy","volume":"2011","author":"Guo","year":"2011","journal-title":"J. Nanomater."},{"issue":"36","key":"10.1016\/j.actbio.2024.09.026_bib0030","doi-asserted-by":"crossref","first-page":"11680","DOI":"10.1021\/jacs.6b05357","article-title":"A Single ssDNA Aptamer Binding to Mannose-Capped Lipoarabinomannan of Bacillus Calmette-Guerin Enhances Immunoprotective Effect against Tuberculosis","volume":"138","author":"Sun","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2024.09.026_bib0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tube.2017.03.010","article-title":"Selection and identification of specific glycoproteins and glycan biomarkers of macrophages involved in Mycobacterium tuberculosis infection","volume":"104","author":"Tang","year":"2017","journal-title":"Tuberculosis (Edinb)"},{"issue":"43","key":"10.1016\/j.actbio.2024.09.026_bib0032","doi-asserted-by":"crossref","first-page":"17253","DOI":"10.1073\/pnas.1308887110","article-title":"Modulation of macrophage phenotype by cell shape","volume":"110","author":"McWhorter","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0033","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1515\/BC.2009.026","article-title":"A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15","volume":"390","author":"Yoon","year":"2009","journal-title":"Biol. Chem."},{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0034","doi-asserted-by":"crossref","first-page":"e12649","DOI":"10.1111\/cpr.12649","article-title":"Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis","volume":"52","author":"Sabir","year":"2019","journal-title":"Cell Prolif"},{"issue":"7","key":"10.1016\/j.actbio.2024.09.026_bib0035","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/pharmaceutics12070604","article-title":"Protein-Based Nanoparticles as Drug Delivery Systems","volume":"12","author":"Hong","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.actbio.2024.09.026_bib0036","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-based nanoparticles as potential controlled release drug delivery systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2024.09.026_bib0037","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0008-6215(00)90605-0","article-title":"Purification and characterization of the D-mannose receptor from J774 mouse macrophage cells","volume":"213","author":"Blum","year":"1991","journal-title":"Carbohydr. Res."},{"issue":"10","key":"10.1016\/j.actbio.2024.09.026_bib0038","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1039\/C7SC04853J","article-title":"Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy","volume":"9","author":"Zhao","year":"2018","journal-title":"Chem. Sci."},{"issue":"15","key":"10.1016\/j.actbio.2024.09.026_bib0039","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121098119","article-title":"Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis","volume":"119","author":"Singh","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.actbio.2024.09.026_bib0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fimmu.2020.00234","article-title":"Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages","volume":"11","author":"Orecchioni","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2024.09.026_bib0041","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","article-title":"RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?","volume":"56","author":"Bobbin","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.actbio.2024.09.026_bib0042","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1023\/A:1018979126326","article-title":"Albumin Microspheres as a Drug-Delivery System - Relation among Turbidity Ratio, Degree of Cross-Linking, and Drug-Release","volume":"10","author":"Rubino","year":"1993","journal-title":"Pharmaceut Res"},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0043","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41551-021-00740-x","article-title":"Inhibition of aberrant tissue remodelling by mesenchymal stromal cells singly coated with soft gels presenting defined chemomechanical cues","volume":"6","author":"Wong","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"6","key":"10.1016\/j.actbio.2024.09.026_bib0044","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3390\/ijms20061350","article-title":"Matrix Metalloproteinases in Pulmonary and Central Nervous System Tuberculosis-A Review","volume":"20","author":"Rohlwink","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"RR-15","key":"10.1016\/j.actbio.2024.09.026_bib0045","first-page":"49","article-title":"N.C.f.H.I.V.S.T.D. Division of Tuberculosis Elimination, C.f.D.C. Tb Prevention, Prevention, Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States","volume":"54","author":"Mazurek","year":"2005","journal-title":"MMWR. Recomm. Rep."},{"key":"10.1016\/j.actbio.2024.09.026_bib0046","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijid.2019.02.004","article-title":"Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali","volume":"81","author":"Baya","year":"2019","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.actbio.2024.09.026_bib0047","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.tips.2012.09.005","article-title":"Targeting the kallikrein-related peptidases for drug development","volume":"33","author":"Sotiropoulou","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.actbio.2024.09.026_bib0048","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.actbio.2021.12.019","article-title":"Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy","volume":"140","author":"Pereira","year":"2022","journal-title":"Acta Biomater"},{"issue":"5","key":"10.1016\/j.actbio.2024.09.026_bib0049","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.eururo.2010.11.024","article-title":"Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"59","author":"Denmeade","year":"2011","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.actbio.2024.09.026_bib0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/geno.2000.6346","article-title":"KLK12 is a novel serine protease and a new member of the human kallikrein gene family - Differential expression in breast cancer","volume":"69","author":"Yousef","year":"2000","journal-title":"Genomics"},{"key":"10.1016\/j.actbio.2024.09.026_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124403","article-title":"Precision arrows: Navigating breast cancer with nanotechnology siRNA","volume":"662","author":"Jayaswal","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0052","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41467-017-00297-x","article-title":"Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells","volume":"8","author":"Cui","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2024.09.026_bib0053","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6673-2-16","article-title":"Nanotechnology-based drug delivery systems","volume":"2","author":"Suri","year":"2007","journal-title":"J. Occup. Med. Toxicol."},{"issue":"6","key":"10.1016\/j.actbio.2024.09.026_bib0054","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.34.6.967","article-title":"Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice","volume":"34","author":"Klemens","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/08982100802610835","article-title":"Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation","volume":"19","author":"Zaru","year":"2009","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.actbio.2024.09.026_bib0056","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0076-6879(05)91016-1","article-title":"Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections","volume":"391","author":"Gupta","year":"2005","journal-title":"Methods Enzymol"},{"issue":"4-5","key":"10.1016\/j.actbio.2024.09.026_bib0057","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejps.2003.09.008","article-title":"Delivery of liposomes in dry powder form: aerodynamic dispersion properties","volume":"20","author":"Desai","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.actbio.2024.09.026_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116978","article-title":"Lipid nanoparticles coated with chitosan using a one-step association method to target rifampicin to alveolar macrophages","volume":"252","author":"Vieira","year":"2021","journal-title":"Carbohydr. Polym."},{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0059","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/adhm.201200109","article-title":"Advanced materials for co-delivery of drugs and genes in cancer therapy","volume":"1","author":"Khan","year":"2012","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/bm801109g","article-title":"Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug","volume":"10","author":"Beh","year":"2009","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0061","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijantimicag.2005.07.012","article-title":"Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis","volume":"26","author":"Ahmad","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5-6","key":"10.1016\/j.actbio.2024.09.026_bib0062","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tube.2005.08.009","article-title":"Oral solid lipid nanoparticle-based antitubercular chemotherapy","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"10.1016\/j.actbio.2024.09.026_bib0063","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkg477","article-title":"Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis","volume":"52","author":"Pandey","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.026_bib0064","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0378-5173(97)04886-2","article-title":"Preparation of hydrophobic and hydrophilic albumin microspheres and determination of surface carboxylic acid and amino residues","volume":"151","author":"MacAdam","year":"1997","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.actbio.2024.09.026_bib0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0378-5173(99)00420-2","article-title":"Desolvation process and surface characteristics of HSA-nanoparticles","volume":"196","author":"Weber","year":"2000","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.actbio.2024.09.026_bib0066","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41565-019-0381-6","article-title":"Precise targeting of as a therapeutic strategy for human triple negative breast cancer","volume":"14","author":"Xu","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"553","key":"10.1016\/j.actbio.2024.09.026_bib0067","doi-asserted-by":"crossref","first-page":"eaay1063","DOI":"10.1126\/scitranslmed.aay1063","article-title":"siRNA nanoparticles targeting CaMKIIgamma in lesional macrophages improve atherosclerotic plaque stability in mice","volume":"12","author":"Tao","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.actbio.2024.09.026_bib0068","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1378\/chest.125.6.2156","article-title":"Vascular endothelial growth factor levels in active pulmonary tuberculosis","volume":"125","author":"Alatas","year":"2004","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.actbio.2024.09.026_bib0069","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"3","key":"10.1016\/j.actbio.2024.09.026_bib0070","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.3791","article-title":"Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy","volume":"21","author":"Liang","year":"2015","journal-title":"Nat. Med."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124005427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124005427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T08:53:36Z","timestamp":1729328016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706124005427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":70,"alternative-id":["S1742706124005427"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2024.09.026","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles target M2 macrophages to silence kallikrein-related peptidase 12 for the treatment of tuberculosis and drug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2024.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}